Tech Company Financing Transactions
A2 Biotherapeutics Funding Round
On 1/9/2025, A2 Biotherapeutics secured $80 million in Series C funding from Samsara BioCapital and The Column Group.
Transaction Overview
Company Name
Announced On
1/9/2025
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds for three clinical development programs and advancement of its pipeline of CAR-T cell therapies based on its proprietary Tmod� platform technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30301 Agoura Rd. 210
Agoura Hills, CA 91301
USA
Agoura Hills, CA 91301
USA
Phone
Undisclosed
Website
Email Address
Overview
A2 is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Foraker
Chief Operating Officer
David Lucas
Chief Scientific Officer
Alexander Kamb
Browse more venture capital transactions:
Prev: 1/9/2025: Light Horse Therapeutics venture capital transaction
Next: 1/9/2025: ndustrial venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs